Small Cell Lung Cancer Clinical Trials 2024

What are the top hospitals conducting small cell lung cancer research?

Across the United States, top hospitals are leading the charge in clinical trials for small cell lung cancer, a formidable disease that affects many individuals. In Saint Louis, Washington University School of Medicine has emerged as a key player with eight ongoing trials and an impressive track record of 24 completed studies dedicated to this particular form of lung cancer. Their involvement dates back to their first recorded trial in 1992, demonstrating their long-standing commitment to advancing treatment options.

Meanwhile, on the East Coast, Memorial Sloan Kettering Cancer Center in New york is making significant strides with eight active small cell lung cancer trials and an impressive history of 23 previous studies. Notably, their interest in exploring new treatments for this devastating disease began more recently in 2007 but has since grown exponentially.

In Bethesda at the National Institutes of Health Clinical Center, researchers are actively engaged in seven clinical trials focused on small cell lung cancer. Although they have conducted only eight all-time trials thus far - starting their investigation journey relatively recently in 2011 - they showcase dedication and expertise within this specialized field.

The esteemed Dana Farber Cancer Institute located in Boston also plays a crucial role by conducting six active clinical trials centered around small cell lung cancer while having contributed significantly with fifteen past investigations since initiating its exploration into this area back in 2010.

Similarly contributing from Boston's medical landscape is Massachusetts General Hospital which currently boasts five ongoing research projects aimed at unraveling potential breakthroughs for those afflicted by small cell lung cancer; throughout its decade-long journey initiated through first trial marking year2006 till present day,it holds distinguished track-record accomplishing nineteen such experiments

These remarkable institutions symbolize hope and progress within the realm of small cell lung cancer research. As they tirelessly work towards better understanding this complex condition and developing effective therapies through rigorous clinical testing, patients can find solace knowing that these hospitals stand united against one common enemy: bringing us closer to improved outcomes and brighter futures for those battling this devastating disease.

Which are the best cities for small cell lung cancer clinical trials?

When it comes to small cell lung cancer clinical trials, several cities have emerged as prominent centers for research and advancements. Anchorage, Alaska leads the pack with 34 active trials focusing on treatments like High Radiation Dose Therapy, Cisplatin, and Atezolizumab. New york City follows closely behind with 27 ongoing studies investigating PF-07104091 monotherapy dose expansion (ovarian), Radiation Therapy Phase 1b, and more. Boston, Massachusetts also plays a significant role in this field with 25 active trials exploring pembrolizumab, Olaparib, PF-07104091 monotherapy dose expansion (ovarian), among others. Nashville, Tennessee and Saint Louis Missouri also contribute significantly to small cell lung cancer research through their respective active trial efforts. These cities offer individuals battling small cell lung cancer access to cutting-edge clinical trials that pave the way for new treatment options and improved outcomes.

Which are the top treatments for small cell lung cancer being explored in clinical trials?

Small cell lung cancer is a fierce adversary, but the field of clinical trials offers hope for patients. Emerging as top contenders are durvalumab, with an impressive seven ongoing trials and 33 all-time small cell lung cancer trials since its introduction in 2016. Atezolizumab follows closely behind, engaging in five active studies and accumulating 37 all-time trials dedicated to battling this aggressive form of cancer since 2017. Also making waves is nivolumab, participating in four current trials out of a total of 23 ever conducted for small cell lung cancer since its debut in 2014. Not to be overlooked is pembrolizumab, contributing to three ongoing studies and boasting an extensive portfolio of 26 all-time small cell lung cancer trials since first listing also back in 2014. These innovative treatments bring renewed optimism on the horizon for those affected by small cell lung cancer.

What are the most recent clinical trials for small cell lung cancer?

Promising developments in clinical trials offer hope for individuals with small cell lung cancer. The DB-1311 trial, currently in Phase 1 and Phase 2, aims to assess the effectiveness of this treatment specifically designed for small cell lung cancer patients. Another trial combines ADI-PEG, gemcitabine, and docetaxel to evaluate their potential synergy against the disease during its early stages. Additionally, mycophenolate mofetil is being investigated as a potential therapeutic option for those affected by small cell lung cancer. These studies highlight the ongoing efforts to advance treatment options and improve outcomes for individuals battling this challenging form of lung cancer.

What small cell lung cancer clinical trials were recently completed?

Recent advancements in small cell lung cancer research have seen the completion of several significant clinical trials. In July 2021, BeiGene successfully concluded a trial investigating Ociperlimab's potential benefits for patients with this aggressive form of lung cancer. Another noteworthy trial sponsored by EMD Serono Research & Development Institute, Inc., examined the effectiveness of Berzosertib and wrapped up in March 2021. These recent milestones demonstrate ongoing efforts to develop innovative treatments that may improve outcomes for individuals battling small cell lung cancer.